Curis, Inc. (CRIS)

In Q3 2025, Curis reported earnings per share of -$0.49, surpassing analysts' expectations. Over the past year, Curis's stock value has declined significantly, touching a 52-week low in March 2025. In Q2 2025, Curis reported an improved net loss and increased revenues, leading to a moderate positive market reaction. In January 2026, Curis announced the pricing and closing of a private placement. In March 2025, Curis Inc. faced a potential Nasdaq delisting due to non-compliance with market value requirements.

Based on historical stock price data, August has historically shown the highest probability of positive returns, while February has the lowest, suggesting some seasonality in the performance of Curis, Inc. stock. This seasonality likely reflects broader market trends or the timing of company announcements and clinical trial updates rather than direct consumer demand for its products.

Curis, Inc. is a biotechnology company focused on discovering and developing innovative cancer therapeutics, operating within the healthcare sector. The company's main activities involve the research and development of small molecule inhibitors that target cancer-related pathways. Its major products and pipeline candidates include Emavusertib, Erivedge, Fimepinostat, CA-170, and CA-327.

Curis, Inc. is headquartered in Lexington, Massachusetts, United States, and its drug candidates are developed for the treatment of human cancers in the United States. Curis has received supportive feedback from both the FDA and the European Medicines Agency regarding its plans to use data from the TakeAim Lymphoma study to support potential accelerated approval for emavusertib in PCNSL in the U.S. and Europe.

Curis, Inc.'s brand reputation has been influenced by positive clinical developments and financial challenges. Promising results from the TakeAim Leukemia study and Orphan Drug Designation for emavusertib have contributed positively to the company's scientific reputation. The significant decline in stock price and potential Nasdaq delisting have negatively impacted investor confidence and the company's financial reputation.

Curis, Inc. has 45 institutional owners and shareholders holding a total of 4,606,070 shares. Major institutional owners include Bleichroeder LP, Armistice Capital, Llc, Citigroup Inc, M28 Capital Management LP, Vanguard Group Inc, CM Management, LLC, Renaissance Technologies Llc, and Geode Capital Management, Llc. Thomas A. Satterfield Jr. is listed as a major individual owner.